City of Hope Medical Center
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, City of Hope Medical Center sits in the top decile of US sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count).
City of Hope Medical Center: 582 sponsored US clinical trials, 167 recruiting.
City of Hope Medical Center sponsors 582 registered US clinical trials on ClinicalTrials.gov, 167 of them currently recruiting, and 217 completed. 9 of these trials are in Phase 3-4 (later-stage) and 382 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Acute Myeloid Leukemia, with 22 trials.
Top-decile sponsor footprint
City of Hope Medical Center ranks in the top decile of sponsors by registered trial count (#59 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
217 of 245 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (88.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
582 total, page 12 of 12
Cyclophosphamide With or Without Celecoxib in Treating Patients With Recurrent or Persistent Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer
NCT00538031
Tamoxifen, Carboplatin, and Topotecan in Treating Patients With CNS Metastases or Recurrent Brain or Spinal Cord Tumors
NCT00541138
Imatinib Mesylate in Treating Patients With Recurrent Ewing's Family of Tumors or Desmoplastic Small Round-Cell Tumor
NCT00062205
R115777 in Treating Patients With Advanced Solid Tumors
NCT00025454
Nipple Secretion Samples in Detecting Breast Cancer in Patients and Healthy Participants Undergoing Breast Cancer Screening, Breast Diagnostic Studies, or Treatment for Benign Breast Disease
NCT00813878
CCI-779 in Treating Patients With Metastatic Melanoma
NCT00022464
UCN-01 and Cisplatin in Treating Patients With Advanced or Metastatic Solid Tumors
NCT00006464
Chloroquinoxaline Sulfonamide in Treating Patients With Small Cell Lung Cancer
NCT00008372
SU5416 and Interferon Alfa-2b in Treating Patients With Unresectable or Metastatic Kidney Cancer
NCT00006384
SU5416 and Paclitaxel in Treating Patients With Advanced Cancer
NCT00006257
Trastuzumab and Docetaxel in Treating Patients Who Have Metastatic Prostate Cancer That Is Refractory to Hormone Therapy
NCT00005857
Oxaliplatin Plus Capecitabine in Treating Patients With Metastatic or Recurrent Solid Tumor
NCT00005839
Docetaxel and Oxaliplatin in Treating Patients With Metastatic or Recurrent Solid Tumor
NCT00004243
Tirapazamine, Carboplatin, and Paclitaxel in Treating Patients With Advanced Malignant Solid Tumors
NCT00005078
Oxaliplatin in Treating Patients With Advanced Cancer Plus Liver Dysfunction
NCT00005077
Oxaliplatin and Gemcitabine in Treating Patients With Advanced Cancer
NCT00004220
Combination Chemotherapy, Amifostine, and Peripheral Stem Cell Transplantation in Treating Patients With Stage II, Stage III, or Stage IV Breast Cancer
NCT00003927
Combination Chemotherapy in Treating Patients With High-Risk Breast Cancer
NCT00004092
Combination Chemo, Peripheral Stem Cell Transplant, Biological Therapy, Pamidronate and Thalidomide for Multiple Myeloma
NCT00004088
5-Fluoro-2'-Deoxcyctidine and Tetrahydrouridine to Treat Patients With Advanced Cancer
NCT00359606
Ganciclovir by Infusion and by Mouth in Treating Patients With Cytomegalovirus After Donor Bone Marrow Transplant
NCT00530218
Combination Chemotherapy With or Without Total-Body Irradiation Followed By Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma
NCT00559104
Cytomegalovirus Vaccine in Healthy Participants
NCT00712634
Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer
NCT00003042
Vinorelbine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Treatment and Liver Dysfunction
NCT00540982
Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Relapsed Germ Cell Cancer
NCT00002931
Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function
NCT00002901
Paclitaxel With or Without PSC 833 in Treating Patients With Metastatic Breast Cancer
NCT00002937
High-Dose Combination Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Cancer
NCT00002854
Liver Resection and Floxuridine Plus Fluorouracil and Leucovorin in Treating Patients With Liver Metastases From Colorectal Cancer
NCT00002842
Idarubicin and High-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia
NCT00528398
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Sarcoma
NCT00002601
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 240 |
| Phase 2 | 142 |
| Phase 3 | 8 |
| Phase 4 | 1 |
Therapeutic Areas
What is open in the City of Hope Medical Center pipeline
167 recruiting of 582 indexed (29% open); 217 completed (37%).
Phase mix: 9 late (III/IV) vs 382 early (I/II) (early-phase heavy).
Top condition: Acute Myeloid Leukemia (22 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
City of Hope Medical Center: open-pipeline peers nationwide
Peers matched on 582 registered trials and 29% open enrollment, not the therapeutic-area sidebar.
City of Hope Medical Center sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 582 trials (± recruiting share)
- Bayer · 591 trials · 4% recruiting
- Janssen Research & Development · 593 trials · 11% recruiting
- Children's Hospital Medical Center, Cincinnati · 571 trials · 19% recruiting
- National Institute of Neurological Disorders and Stroke (NINDS) · 567 trials · 8% recruiting
Sponsors near 29% open enrollment (± trial volume)
- Methodist Health System · 29% recruiting · 125 trials
- 89bio · 29% recruiting · 7 trials
- Alabama Physical Therapy & Acupuncture · 29% recruiting · 14 trials
- AlloSource · 29% recruiting · 7 trials
Related
What to do with this City of Hope Medical Center page
582 registered trials is a research-attention snapshot, not an endorsement of City of Hope Medical Center or any single study.
- 167 of City of Hope Medical Center's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Acute Myeloid Leukemia is the condition City of Hope Medical Center studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Acute Myeloid Leukemia trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. City of Hope Medical Center pipeline card: 582 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.